> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Zasocitinib Beats Sotyktu in Head-to-Head Study: Takeda
- URL: https://www.fdaweb.com/zasocitinib-beats-sotyktu-in-head-to-head-study-takeda/
- Published: 2026-06-11T12:00:00.000Z
- Updated: 2026-09-14T13:41:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161294

Takeda says its zasocitinib significantly outperformed Bristol Myers Squibb’s Sotyktu (deucravacitinib) in the LATITUDE Atlas Phase 3 head-to-head psoriasis study. A Takeda [statement](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-outperforms-deucravacitinib-study/?ref=fdaweb.com) says that more than 35% of zasocitinib-treated patients achieved complete skin clearance at week 16, more than 2.5 times the Sotyktu response rate. It says the study also demonstrated statistical superiority over Sotyktu for all key secondary endpoints. The drug was generally well tolerated with a consistent safety and tolerability profile, and no new safety signals were identified, Takeda says.

Zasocitinib (TAK-279) is described as an investigational, next-generation, highly selective and potent oral TYK2 inhibitor that maintains 24-hour inhibition of IL-23 plus other core disease-driving immune pathways. Takeda says it is currently studying zasocitinib safety and effectiveness in Phase 3 studies in psoriatic arthritis and Phase 2 studies in Crohn’s disease, ulcerative colitis, vitiligo, and hidradentis suppurativa.